Myositis: An update on pathogenesis

Current Opinion in Rheumatology

Volumn 16, Issue 6, 2004, Pages 700-706

  Christopher Stine, Lisa ^a   Plotz, Paul H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathy; Pathogenesis; Polymyositis

Indexed keywords

MYOSIN HEAVY CHAIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; BIODIVERSITY; CELL ADHESION; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC SUSCEPTIBILITY; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; MEDICAL RESEARCH; MUSCLE CELL; MUSCLE INJURY; MYOSITIS; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; RISK FACTOR;

ANIMALS; HUMANS; MYOSITIS; RISK FACTORS;

EID: 7244253273     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000141925.21941.d8     Document Type: Review

References (50)

1. Andersson J, Englund P, Sunnemark D, et al.: CBA/J mice infected with Trypanosoma cruzi: an experimental model for inflammatory myopathies. Muscle Nerve 2003, 27:442-448. Despite the apparent remoteness of this parasite-induced disease from the apparently autoimmune pathology of human idiopathic inflammatory myopathy, this model mimics the pathologic picture closer than most others. It may, however, prove too remote and unfamiliar to be attractive to other investigators.
2. Smith RD, Konoplev S, DeCourten-Myers G, Brown T: West Nile virus encephalitis with myositis and orchitis. Hum Pathol 2004, 35:254-258.
3. Petersen LR, Marfin AA: West Nile virus: a primer for the clinician. Ann Intern Med 2002, 137:173-179.
4. Douche-Aourik F, Berlier W, Feasson L, et al.: Detection of enterovirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. J Med Virol 2003, 71:540-547.
5. Leff RL, Love LA, Miller FW, et al.: Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992, 339:1192-1195.
6. Chevrel G, Borsotti JP, Miossec P: Lack of evidence for a direct involvement of muscle infection by parvovirus B19 in the pathogenesis of inflammatory myopathies: a follow-up study. Rheumatology (Oxford) 2003, 42:349-352.
7. Fathi M, Dastmalchi M, Rasmussen E, et al.: Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004, 63:297-301. A fine report of a large experience with a remarkably high proportion of patients with lung involvement.
8. Schnabel A, Reuter M, Biederer J, et al.: Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003, 32:273-284. Another nicely studied series with a relatively high incidence of lung involvement. It seems likely that there will turn out to be common microenvironmental factors in the lungs and the skeletal muscle to account for the high prevalence of concomitant pathology and the autoantibodies-directed to aminoacyl-tRNA synthetases-found in patients with both lung and muscle involvement.
9. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al.: Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003, 22:245-250.
10. High WA, Cohen JB, Murphy BA, Costner MI: Fatal interstitial pulmonary fibrosis in anti-Jo-1 -negative amyopathic dermatomyositis. J Am Acad Dermatol 2003, 49:295-298.
11. Bronner IM, Hoogendijk JE, Wintzen AR, et al.: Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003, 250:480-485.
12. De Bleecker J, Vervaet V, Van den Bergh P: Necrotizing myopathy with microvascular deposition of the complement membrane attack complex. Clin Neuropathol 2004, 23:76-79. The papers of Bronner [11] and De Bleecker resemble earlier observations on the necrotizing myopathy with little or no inflammation seen in patients with anti-SRP autoantibodies.
13. Okada S, Weatherhead E, Targoff IN, et al.: Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003, 48:2285-2293. A group of clinicians from around the around the world with expertise in myositis joined together by Dr. Fred Miller and his colleagues in the National Institute of Environmental Health Sciences at NIH have made an excellent advance in providing a plausible model for how an environmental factor might influence the phenotype of a disease with a strong genetic component. Their success depended upon starting with a good hypothesis.
14. Werth VP, Bashir M, Zhang W: Photosensitivity in rheumatic diseases. J Investig Dermatol Symp Proc 2004, 9:57-63.
15. Kuru S, Inukai A, Kato T, et al.: Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 2003, 105:217-224.
16. Hengstman GJ, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10-15.
17. Musial J, Undas A, Celinska-Lowenhoff M: Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:1566-1568.
18. Wiendl H, Mitsdoerffer M, Schneider D, et al.: Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003, 17:1892-1894. This is a follow-up of important earlier observations on this newly recognized costimulatory path.
19. Wiendl H, Mitsdoerffer M, Schneider D, et al.: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003, 126:1026-1035. Another possibly important co-stimulatory pair identified by this group adds expected complexity to the picture of pathogenesis.
20. van der Pas J, Hengstman GJ, ter Laak HJ, et al.: Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004, 75:136-139.
21. Civatte M, Schleinitz N, Krammer P, et al.: Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 2003, 29:546-552.
22. De Paepe B, Schroder JM, Martin JJ, et al.: Localization of the alpha-chemokine SDF-1 and its receptor CXCR4 in idiopathic inflammatory myopathies. Neuromuscul Disord 2004, 14:265-273.
23. Hofbauer M, Wiesener S, Babbe H, et al.: Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci USA 2003, 100:4090-4095. An impressive array of highly sensitive techniques have been brought together to explore important questions about individual immune cells that inhabit the inflammatory lesions in myositis. A tour de force.
24. Lindvall B, Dahlbom K, Henriksson KG, et al.: The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand 2003, 107:134-141.
25. Sewry CA, Dubowitz V, Abraha A, et al.: Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J Neurol Sci 1987, 81:141-153.
26. Louboutin JP, Navenot JM, Rouger K, Blanchard D: S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. Muscle Nerve 2003, 27:575-581.
27. Andres N, Lizcano JM, Rodriguez MJ, et al.: Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 2001, 49:209-217. This is an intriguing new window on the very local events where the damage is occurring.
28. Olive M, Unzeta M, Moreno D, Ferrer I: Overexpression of semicarbazide-sensitive amine oxidase in human myopathies. Muscle Nerve 2004, 29:261-266.
29. Choi YC, Kim TS, Kim SY: Increase in transglutaminase 2 in idiopathic inflammatory myopathies. Eur Neurol 2004, 51:10-14.
30. Watkins J, Farzaneh-Far R, Tahir H, et al.: Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 2004, 43:389-390.
31. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al.: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
32. Rider LG, Shamim E, Okada S, et al.: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42:1285-1290.
33. Hassan AB, Nikitina-Zake L, Sanjeevi CB, et al.: Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004, 50:1013-1015.
34. Lampe JB, Gossrau G, Kempe A, et al.: Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol 2003, 250:1313-1317.
35. Lambert NC, Evans PC, Hashizumi TL, et al.: Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501 : implications in autoimmunity. J Immunol 2000, 164:5545-5548.
36. Artlett CM, O'Hanlon TP, Lopez AM, et al.: HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum 2003, 48:2567-2572.
37. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Labrador-Horrillos M, et al.: Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 2003, 42:1016-1018.
38. Derk CT, Vivino FB, Kenyon L, Mandel S: Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol 2003, 22:324-328.
39. Muntzing K, Lindberg C, Moslemi AR, Oldfors A: Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003, 58:195-200.
40. Vattemi G, Engel WK, McFerrin J, Askanas V: Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004, 164:1-7.
41. Tsuruta Y, Furuta A, Furuta K, et al.: Expression of the lysosome-associated membrane proteins in myopathies with rimmed vacuoles. Acta Neuropathol (Berl) 2001, 101:579-584.
42. Kumamoto T, Ueyama H, Tsumura H, et al.: Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis. Acta Neuropathol (Berl) 2004, 107:59-65.
43. Kovacs GG, Lindeck-Pozza E, Chimelli L, et al.: Creutzfeldt-Jakob disease and inclusion body myositis: abundant disease-associated prion protein in muscle. Ann Neurol 2004, 55:121-125.
44. Huizing M, Rakocevic G, Sparks SE, et al.: Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab 2004, 81:196-202. This study is an imaginative approach to make the connection between a known genetic lesion and a distant clinical symptom.
45. Yabe I, Higashi T, Kikuchi S, et al.: GNE mutations causing distal myopathy with rimmed vacuoles with inflammation. Neurology 2003, 61:384-386. An interesting and welcome complexity that suggests that it is highly likely that inflammation in many circumstances in muscle disease will one day be discovered to be a secondary event.
46. Krause S, Schlotter-Weigel B, Walter MC, et al.: A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. Neuromuscul Disord 2003, 13:830-834.
47. Argov Z, Eisenberg I, Grabov-Nardini G, et al.: Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. Neurology 2003, 60:1519-1523.
48. Del Bo R, Baron P, Prelle A, et al.: Novel missense mutation and large deletion of GNE gene in autosomal-recessive inclusion-body myopathy. Muscle Nerve 2003, 28:113-117.
49. Watts GD, Thorne M, Kovach MJ, et al.: Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes. Neuromuscul Disord 2003, 13:559-567.
50. Fidzianska A, Rowinska-Marcinska K, Hausmanowa-Petrusewicz I: Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol (Berl) 2004, 107:197-203.